Etrolizumab for induction of remission in ulcerative colitis

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 12, 2015, Pages

  Rosenfeld, Greg ^a   Parker, Claire E ^b   Macdonald, John K ^b   Bressler, Brian ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ETROLIZUMAB; MONOCLONAL ANTIBODY;

ADVERSE EVENT; COMPARATIVE EFFECTIVENESS; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; REVIEW; SYSTEMATIC REVIEW; ULCERATIVE COLITIS; ADVERSE EFFECTS; COLITIS, ULCERATIVE; INDUCTION CHEMOTHERAPY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); TIME FACTOR;

ANTIBODIES, MONOCLONAL, HUMANIZED; COLITIS, ULCERATIVE; HUMANS; INDUCTION CHEMOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS;

EID: 84965185786     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD011661.pub2     Document Type: Review

References (55)

1. Rutgeerts PJ, Fedorak RN, Hommes DW, Sturm A, Baumgart DC, Bressler B. A phase I study of rhuMab beta7 in moderate to severe ulcerative colitis (UC). Gastroenterology 2011;140(5 Suppl 1):S-125.
2. Rutgeerts PJ, Fedorak RN, Hommes DW, Sturm A, Baumgart DC, Bressler B, et al. A randomised phase i study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis. Gut 2013;62(8):1122-30.
3. Keir M, Tew G, Luca W, Eastham-Anderson D, Diehl J, Egen LG, et al. AlphaE integrin expression as a predictive biomarker for induction of clinical remission by etrolizumab: Analysis of a phase II trial in moderate-to-severely active ulcerative colitis. Journal of Crohn's and Colitis 2014;8:S7.
4. Keir M, Tew G, Luca W, Eastham-Anderson D, Diehl J, Egen LG, et al. Alphae integrin expression as a predictive biomarker for induction of clinical remission by etrolizumab: Analysis of a phase ii trial in moderate-to-severely active ulcerative colitis. Gastroenterology 2014;146(Suppl 1):S-422.
5. Vermeire S, O'Byrne S, Williams M, Mansfield JC, Feagan BG, Panes J, et al. Differentiation between etrolizumab (rhumab beta7) and placebo in the eucalyptus phase ii randomized double-blind placebo-controlled induction study to evaluate efficacy and safety in patients with refractory moderate-to-severely active ulcerative colitis. Gastroenterology 2013;144(5):S-36.
6. Vermeire S, O'Byrne S, Keir M, Williams M, Lu T, Mansfield JC, et al. Etrolizumab as induction therapy for ulcerative colitis:a randomised, controlled, phase 2 trial. Lancet 2014;384(9940):309-18.
7. Armuzzi A, Felice C. Etrolizumab in moderate-to-severe ulcerative colitis. Lancet 2014;384(9940):285-6.
8. Fiorino G, Danese S. Etrolizumab in ulcerative colitis: tightening leukocyte traffic control in the inflamed mucosa. Gastroenterology 2014;147(6):1433-5.
9. Kreutzkamp, B. Moderate to severe treatment-resistant ulcerative colitis: Integrin inhibitor etrolizumab leads to clinical remission [Masige bis schwere, therapierefraktare Colitis ulcerosa: Integrinhemmer Etrolizumab fuhrt in klinische Remission]. Arzneimitteltherapie 2014;32(11):309-18.
10. Lin K K, Mahadevan, U. Etrolizumab: anti-beta7-a novel therapy for ulcerative colitis. Gastroenterology 2014;146(1):307-9.
11. NCT01461317. A phase II open-label extension study to evaluate the long-term safety of rhuMAb beta7 in patients with moderate to severe ulcerative colitis. clinicaltrials.gov/ct2/show/NCT01461317 (accessed 19 November 2015).
12. NCT02100696. Phase III, double blind, placebo-controlled, multicenter study of the efficacy and safety of etrolizumab during induction and maintenance in patients with moderate to severe active ulcerative colitis who are refractory to or intolerant of TNF inhibitors. clinicaltrials.gov/ct2/show/NCT02100696 (accessed 19 November 2015).
13. NCT02118584. An open label extension and safety monitoring study of moderate to severe ulcerative colitis patients previously enrolled in etrolizumab phase III studies. clinicaltrials.gov/ct2/show/NCT02118584 (accessed 19 November 2015).
14. NCT02136069. Phase III, randomized, multicenter double-blind, double dummy study to evaluate the efficacy and safety of etrolizumab compared with infliximab in patients with moderate to severe active ulcerative colitis who are naive to TNF inhibitors. clinicaltrials.gov/ct2/show/NCT02136069 (accessed 19 November 2015).
15. NCT02163759. A phase III, randomized, double-blind, double-dummy, placebo-controlled, multicenter study to evaluate the efficacy (induction of remission) and safety of etrolizumab compared with adalimumab and placebo in patients with moderate to severe ulcerative colitis in patients who are naive to TNF inhibitors (Study #1). clinicaltrials.gov/ct2/show/NCT02163759 (accessed 19 November 2015).
16. NCT02165215. Phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy (maintenance of remission) and safety of etrolizumab compared with placebo in patients with moderate to severe active ulcerative colitis who are naive to TNF inhibitors. clinicaltrials.gov/ct2/show/NCT02165215 (accessed 19 November 2015).
17. NCT02171429. Phase III, randomized, double-blind, double-dummy, placebo-controlled, multicenter study to evaluate the efficacy (induction and remission) and safety of etrolizumab compared with adalimumab and placebo in patients with moderate to severe ulcerative colitis in patients who are naive to TNF inhibitors (Study #2). clinicaltrials.gov/ct2/show/NCT02171429 (accessed 19 November 2015).
18. Ariyaratnam J, Subramanian V. Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis. American Journal of Gastroenterology 2014;109(2):163-9.
19. Bickston SJ, Behm BW, Tsoulis DJ, Cheng J, MacDonald JK, Khanna R, et al. Vedolizumab for induction and maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2014, Issue 8. [DOI: 10.1002/14651858.CD007571.pub2]
20. Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with inflammatory bowel disease. Gut 1997;40(2):228-33.
21. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nature Reviews Immunology 2003;3(7):521-33.
22. Cepek KL, Parker CM, Madara JL, Brenner MB. Integrin alpha E beta 7 mediates adhesion of T lymphocytes to epithelial cells. Journal of Immunology 1993;150(8 Pt 1):3459-70.
23. Cohen RD, Yu AP, Wu EQ, Xie J, Mulani PM, Chao J. Systematic review: the costs of ulcerative colitis in Western countries. Alimentary Pharmacology and Therapeutics 2010;31(7):693-707.
24. Danese S, Fiocchi C. Ulcerative colitis. New England Journal of Medicine 2011;365(18):1713-25.
25. Dignass A, Van Assche G, Lindsay JO, Lémann M, Söderholm J, Colombel JF, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. Journal of Crohn's and Colitis 2010;4(1):28-62.
26. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34.
27. Faubion WA, Loftus EV, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121(2):255-60.
28. Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2012, Issue 10. [DOI: 10.1002/14651858.CD000543.pub3]
29. Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2012, Issue 10. [DOI: 10.1002/14651858.CD000544.pub3]
30. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine 2013;369(8):699-710.
31. Fedorak RN, Wong K, Bridges R. Canadian Digestive Health Foundation Public Impact Series. Inflammatory bowel disease in Canada: Incidence, prevalence, and direct and indirect economic impact. Canadian Journal of Gastroenterology 2010;24(11):651-5.
32. Ford AC, Achkar JP, Khan KJ, Kane SV, Talley NJ, Marshall JK, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. American Journal of Gastroenterology 2011;106(4):601-16.
33. Ford AC, Bernstein CN, Khan KJ, Abreu MT, Marshall JK, Talley NJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. American Journal of Gastroenterology 2011;106(4):590-9; quiz 600.
34. Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-alpha therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. American Journal of Gastroenterology 2013;108(8):1268-76.
35. Gisbert JP, Marin AC, McNicholl AG, Chaparro M. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Alimentary Pharmacology and Therapeutics 2015;41(7):613-23.
36. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating high quality evidence and strength of recommendations. BMJ 2008;336(7650):924-6.
37. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
38. Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
39. Holzmann B, McIntyre BW, Weissman IL. Identification of a murine Peyer's patch--specific lymphocyte homing receptor as an integrin molecule with an alpha chain homologous to human VLA-4 alpha. Cell 1989;56(1):37-46.
40. Hu MC, Crowe DT, Weissman IL, Holzmann B. Cloning and expression of mouse integrin beta p(beta 7): a functional role in Peyer's patch-specific lymphocyte homing. Proceedings of the National Academy of Sciences of the United States of America 1992;89(17):8254-8.
41. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. American Journal of Gastroenterology 2010;105(3):501-23; quiz 524.
42. Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD005112.pub2]
43. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006;130(3):940-87.
44. Loftus EV, Delgado DJ, Friedman HS, Sandorn WJ. Colectomy and the incidence of postsurgical complications among ulcerative colitis patients with private health insurance in the United States. American Journal of Gastroenterology 2008;103(7):1737-45.
45. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142(1):46-54.e42; quiz e30.
46. Podolsky DK. Inflammatory bowel disease. New EnglandJournal of Medicine 2002;347(6):417-29.
47. Reinisch W, Sandborn WJ, Hommes DW, D'Haens G, Hanauer S, Schreiber S, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011;60(6):780-7. [PUBMED: 21209123]
48. Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D'Haens G, Wolf DC, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142(2):257-65.e1-3.
49. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014;146(1):85-95; quiz e14-5.
50. Schünemann HJ, Oxford AD, Visit GE, Higgins JPT, Deeks, JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook of Systematic Reviews of Intervetions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Availble from www.cochrane-handbook.org.
51. Smith MA, Irving PM, Marinaki AM, Sanderson JD. Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease. Alimentary Pharmacology and Therapeutics 2010;32(2):119-30.
52. Stefanich EG, Danilenko DM, Wang H, O'Byrne S, Erickson R, Gelzleichter T, et al. A humanized monoclonal antibody targeting the beta7 integrin selectively blocks intestinal homing of T lymphocytes. British Journal of Pharmacology 2011;162(8):1855-70.
53. Timmer A, McDonald JWD, Tsoulis DJ, MacDonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD000478.pub3]
54. Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clinical Gastroenterology and Hepatology 2007;5(1):103-10.
55. Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. New England Journal of Medicine 2005;353:362-8.